How does MetLife's stock performance stack up against other insurance companies?

Overview of MetLife, Inc.

Headquartered in New York, MetLife, Inc. (MET) is a global provider of financial services, offering products such as insurance, annuities, employee benefits, and asset management. With a market capitalization of $47.3 billion, MetLife operates across several segments, including Group Benefits, Retirement and Income Solutions, Asia, Latin America, Europe, the Middle East and Africa, as well as MetLife Holdings.

Large-Cap Status and Industry Influence

Stocks with a market value of $10 billion or more are generally classified as large-cap. MetLife comfortably fits this category, highlighting its significant presence and impact within the life insurance sector.

Recent Stock Performance

Currently, MetLife’s share price is trading 14.5% below its 52-week peak of $85, which was reached on March 25, 2025. Over the last quarter, MET’s value has dropped by 6.2%, underperforming the State Street SPDR S&P Insurance ETF (KIE), which saw a smaller decline of 1.5% during the same period.

Source: www.barchart.com

Long-Term Trends and Technical Analysis

Looking at the past year, MetLife’s stock has fallen by 15.2%, a steeper decline compared to KIE’s 3.6% drop. Since the end of February, MET has consistently traded below both its 200-day and 50-day moving averages, signaling ongoing bearish momentum.

Source: www.barchart.com

Recent Earnings and Peer Comparison

Following the release of its mixed fourth-quarter 2025 earnings on February 5, MetLife’s shares slipped by 3.5%. The company reported a 29% year-over-year increase in adjusted premiums, fees, and other revenues, totaling $18.6 billion, though this figure missed analyst expectations. However, adjusted earnings per share reached $2.49, surpassing Wall Street forecasts.

In comparison, Aflac Incorporated (AFL), a competitor, saw its stock rise by 2.1% over the past year, outperforming MetLife’s results.

Analyst Outlook

Analysts remain cautiously optimistic about MetLife. Out of 18 analysts covering the stock, the consensus rating is “Moderate Buy.” The average price target is $92.47, indicating a potential upside of 27.2% from current levels.

Disclosure and Source

Disclosure: At the time of writing, Anushka Mukherjee did not hold any positions, directly or indirectly, in the securities discussed. All data and information provided are for informational purposes only. This article was first published on Barchart.com.